Selinexor: Changing the paradigm in patients with TP53 wild-type endometrial cancer?

Mohamed A Gouda; Kyaw Z Thein

doi:10.1016/j.medj.2023.10.005

Selinexor: Changing the paradigm in patients with TP53 wild-type endometrial cancer?

Med. 2023 Nov 10;4(11):752-754. doi: 10.1016/j.medj.2023.10.005.

Authors

Mohamed A Gouda¹, Kyaw Z Thein²

Affiliations

¹ Department of Investigational Cancer Therapeutics (A Phase I Program),The University of Texas M.D. Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX 77030, USA.
² Comprehensive Cancer Centers of Nevada - Central Valley, 3730 S Eastern Avenue, Las Vegas, NV 89169, USA; Kirk Kerkorian School of Medicine at University of Nevada, Las Vegas (UNLV), 4505 S. Maryland Pkwy, Las Vegas, NV 89154, USA; Touro University Nevada, 874 American Pacific Dr, Henderson, NV 89014, USA. Electronic address: kyaw.thein@usoncology.com.

PMID: 37951208
DOI: 10.1016/j.medj.2023.10.005

Abstract

Recurrent endometrial cancer (EC) remains a therapeutic challenge despite advancements in personalized medicine. SIENDO trial showed the potential clinical benefit of selinexor in patients with TP53 wild-type advanced/recurrent EC. The quest for novel therapeutic avenues and approaches continues as researchers seek a glimmer of hope in an area of uncertainty.

MeSH terms

Endometrial Neoplasms* / drug therapy
Endometrial Neoplasms* / genetics
Female
Humans
Hydrazines / pharmacology
Hydrazines / therapeutic use
Neoplasm Recurrence, Local* / drug therapy
Neoplasm Recurrence, Local* / genetics
Triazoles / therapeutic use
Tumor Suppressor Protein p53 / genetics
Tumor Suppressor Protein p53 / therapeutic use

Substances

selinexor
Hydrazines
Triazoles
TP53 protein, human
Tumor Suppressor Protein p53